Skip to main content
  • About
  • News & Events
  • Careers
  • Contact
  • Subscribe
FR
Canada’s Drug Agency | Drugs, Health Technologies and Systems.
  • Find Reports
    • Programs & Initiatives
      • Aging in Place
      • Appropriate Use
      • Canadian Medical Imaging Inventory
      • Drugs for Rare Diseases
      • Emergency Department Overcrowding
      • Health Technology Reviews
      • Horizon Scans
      • Post-Market Drug Evaluation
      • Reimbursement Reviews
      • Scientific Advice
    • Methods
      • Conflict of Interest
      • Methodological Guidelines
      • Program Procedures
    • Tools & Publications
      • Common Acronyms
      • Evidence Bundles
      • HTA Excel Tools
      • Finding the Evidence: Literature Searching Tools in Support of Systematic Reviews
      • Canadian Journal of Health Technologies
    • Provide Input
      • Current Opportunities
      • Instructions
      • Procedures & Templates
    • Engage
      • Sponsor a Reimbursement Review
      • Request Scientific Advice
      • Request an Evidence Review
    • Community Involvement
      • Collaboration and Outreach
      • Patient Groups
      • Pan-Canadian Collaborative
Canada’s Drug Agency | Drugs, Health Technologies and Systems.
FR
  • Find Reports
  • Our Work
    • Programs & Initiatives
      • Advisory Panel: Pan-Canadian Prescription Drug List
      • Aging in Place
      • Appropriate Use
      • Canadian Medical Imaging Inventory
      • Drugs for Rare Diseases
      • Emergency Department Overcrowding
      • Health Technology Reviews
      • Horizon Scans
      • Post-Market Drug Evaluation
      • Reimbursement Reviews
      • Scientific Advice
    • Methods
      • Conflict of Interest
      • Methodological Guidelines
      • Program Procedures
    • Tools & Publications
      • Common Acronyms
      • Evidence Bundles
      • HTA Excel Tools
      • Finding the Evidence: Literature Searching Tools in Support of Systematic Reviews
      • Canadian Journal of Health Technologies
  • Get Involved
    • Provide Input
      • Current Opportunities
      • Instructions
      • Procedures & Templates
    • Engage
      • Sponsor a Reimbursement Review
      • Request Scientific Advice
      • Request an Evidence Review
    • Community Involvement
      • Collaboration and Outreach
      • Patient Groups
      • Pan-Canadian Collaborative
  • About
  • News & Events
  • Careers
  • Contact
  • Subscribe
Submitted by Anonymous (not verified) on Mon, 11/05/2018 - 09:52
EB Summary

Second- and Third-Line Therapy for Patients with Type 2 Diabetes

Link
Second-line therapy in patients with type 2 diabetes inadequately controlled wi…
Date Published
Wed, 10/17/2018 - 12:00
Link Type
PDF

Canada’s Drug Agency is a pan-Canadian health organization, created and funded by Canada’s federal, provincial, and territorial governments.

We provide Canada’s health system leaders with independent evidence and advice so they can make informed drug, health technology, and health system decisions, and we collaborate with national and international partners to enhance our collective impact. 

  • Reports
  • Contact
  • Careers
  • Help

Stay up to date on the latest from Canada’s Drug Agency by subscribing to our newsletter.

Already subscribed? Update your preferences.

  • visit us on facebook
  • visit us on linkedin
  • visit us on youtube
  • visit us on instagram

© 2025 Canadian Agency for Drugs and Technologies in Health

  • Privacy Policy
  • Terms of Use
  • Accessibility
  • Request for Archived Report
Back to Top